{
  "id": 12375604,
  "title": "Canaccord raises Helen of Troy stock price target on sales recovery",
  "url": "https://urgent.news/2026/10/06/canaccord-raises-helen-of-troy-stock-price-target-on-sales-recovery",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T11:56:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/canaccord-raises-helen-of-troy-stock-price-target-on-sales-recovery-93CH-4934209"
  },
  "original_language": "en",
  "account": "Investing.com reports that Canaccord has increased its price target on Helen of Troy (NASDAQ:HELE) shares to $26.00 from $25.00, maintaining a Hold rating. The firm expects the stock to outperform its Fair Value estimate of $25.64. Canaccord anticipates strong growth in both the Home & Outdoor category and Beauty & Wellness segments for fiscal 2027, beginning with the company's Q2 results on October 8. The Home & Outdoor segment is driven by well-known brands like Oxo, Hydro Flask, and Osprey, while the Beauty & Wellness segment is seen as benefiting from the popularity of DIY nail solutions from Olive & June. Improvement in gross margins is expected as the company navigates higher-cost tariff inventory and cost-leveraging in selling, general, and administrative expenses. Canaccord will closely monitor CEO Scott Uzzell's strategic decisions, including investments in the business, debt reduction, potential mergers and acquisitions, and cash returns to shareholders. The price target increase reflects recovering sales trends and positive growth expectations for the fiscal year, but Canaccord still maintains a wait-and-see approach until the company demonstrates consistent revenue and profit growth. Recently, Helen of Troy posted strong first-quarter fiscal 2027 results, surpassing Wall Street's expectations with adjusted earnings of $0.17 per share and revenue of $402.1 million. Despite these positive figures, investor sentiment remains cautious due to concerns over margin pressure, tariff costs, and supply-chain risks. UBS has also maintained a Neutral rating on the stock, while Canaccord has raised its price target to $25 from $23, citing sales growth in the Home & Outdoor and Beauty & Wellness segments.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Canaccord raises Pulse Biosciences stock price target on tech potential",
        "url": "https://urgent.news/2026/10/06/canaccord-raises-pulse-biosciences-stock-price-target-on-tech",
        "published": "2026-10-06T11:56:57.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}